Journal article
The premarket assessment of the cost-effectiveness of a predictive technology “Straticyte™” for the early detection of oral cancer: a decision analytic model
Abstract
IntroductionApproximately half of oral cancers are detected in advanced stages. The current gold standard is histopathological assessment of biopsied tissue, which is subjective and dependent on expertise. Straticyte™, a novel prognostic tool at the pre-market stage, that more accurately identifies patients at high risk for oral cancer than histopathology alone. This study conducts an early cost-effectiveness analysis (CEA) of Straticyte™ and …
Authors
Khoudigian-Sinani S; Blackhouse G; Levine M; Thabane L; O’Reilly D
Journal
Health Economics Review, Vol. 7, No. 1,
Publisher
Springer Nature
Publication Date
December 2017
DOI
10.1186/s13561-017-0170-6
ISSN
2191-1991